Kuo-Hsuan Hsu
Overview
Explore the profile of Kuo-Hsuan Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
928
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wang C, Hsu K, Chang Y, Ho C, Chiang C, Chen K, et al.
J Thorac Oncol
. 2023 Jul;
18(11):1492-1503.
PMID: 37414358
Introduction: The role of a family history of lung cancer (LCFH) in screening using low-dose computed tomography (LDCT) has not been prospectively investigated with long-term follow-up. Methods: A multicenter prospective...
12.
Chen K, Huang Y, Hsu K, Tseng J, Chang G, Yang T
Onco Targets Ther
. 2023 May;
16:317-326.
PMID: 37220494
Purpose: Although serum neutrophil-to-lymphocyte ratio (NLR) is correlated with the outcome of various cancer types, its role in treatment-naïve, advanced, ()-mutant non-small cell lung cancer (NSCLC) patients treated with osimertinib...
13.
Lee P, Chiang C, Tseng J, Zheng Z, Chen K, Chu C, et al.
Front Oncol
. 2023 Mar;
13:1096683.
PMID: 36925928
Introduction: For patients with T2aN0 stage IB lung adenocarcinoma, benefits of adjuvant chemotherapy remain controversial. Here, we aimed to evaluate such benefits. Methods: This retrospective cohort study was conducted on...
14.
Liu Y, Tseng T, Wu C, Cho S, Kuo C, Huang X, et al.
Plant Sci
. 2023 Feb;
330:111634.
PMID: 36775071
Class I small heat shock proteins (CI sHSPs), OsHsp16.9A and OsHsp18.0, share 74% identity in amino acid sequences and accumulate in response to heat shock treatments. Individual rice transformants overexpressing...
15.
Lee P, Huang Y, Hsu Y, Chen K, Hsu K, Lin H, et al.
J Clin Med
. 2023 Jan;
12(1).
PMID: 36615034
(1) Background: We aimed to evaluate the risk of hepatitis B virus (HBV) reactivation in lung cancer patients treated with tyrosine kinase inhibitor (TKI), particularly in those with resolved HBV...
16.
Huang Y, Hsu K, Tseng J, Yang T, Chen K, Su K, et al.
Target Oncol
. 2022 Nov;
18(1):179-180.
PMID: 36334173
No abstract available.
17.
Wu J, Huang J, Hsu K, Huang Y, Chen K, Tseng J, et al.
Anticancer Drugs
. 2022 Oct;
33(10):e842-e849.
PMID: 36206101
Objective: Immunotherapy plus etoposide and platinum (EP)-based chemotherapy is the standard of care for patients with extensive stage-small cell lung carcinoma (ES-SCLC). In the era of immunotherapy, the role of...
18.
Chu C, Huang Y, Lee P, Hsu K, Chen K, Su K, et al.
PLoS One
. 2022 Aug;
17(8):e0273207.
PMID: 35980949
We aimed to evaluate whether different driver mutations have varying impacts on the programmed cell death-ligand 1 (PD-L1) expression of non-small cell lung cancer (NSCLC), and whether the prognostic roles...
19.
Lee P, Huang Y, Lin H, Hsu K, Chen K, Tseng J, et al.
Medicina (Kaunas)
. 2022 Jul;
58(7).
PMID: 35888627
: Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is one of the standard-of-care therapies in patients with -mutant lung adenocarcinoma; however, acquired resistance inevitably developed. Despite the proposition...
20.
Liao P, Ou W, Su K, Sun M, Huang C, Chen K, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740489
Background: We aim to evaluate the influence of the timing of leptomeningeal metastasis (LM) occurrence on the outcome of -mutant lung adenocarcinoma and to explore the predictors of detectable mutation...